CMS announced a final mandatory payment model for certain Medicare Part B drugs that uses international benchmark pricing. The agency said the model is intended to lower drug prices for beneficiaries in Original Medicare and marks a significant Medicare payment-policy change. As a finalized nationwide payment initiative, it is materially different from prior coverage on drug price negotiation and other Medicare program updates.
